Therapeutic Vaccines Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast till 2031

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2024-2031

Therapeutic Vaccines Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Cancer Vaccines, Infectious Disease Vaccines, and Others), Technology (Allogenic Vaccines and Autologous Vaccines), End User (Hospitals, Clinics, and Others), and Geography

  • Report Date : Feb 2025
  • Report Code : TIPRE00039849
  • Category : Life Sciences
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 207
Page Updated: Feb 2025

AI overview of Therapeutic Vaccines Market


The Therapeutic Vaccines Market is poised for significant growth, projected to reach a market size of approximately US$ 2,934.57 million by 2031, up from US$ 1,244.94 million in 2024, reflecting a robust CAGR of 13.0% during the forecast period from 2024 to 2031. This market encompasses various segments, including cancer and infectious disease vaccines, with key end users being hospitals and clinics. A major driver of this growth is the rising prevalence of chronic conditions, which is prompting increased investments and funding for vaccine development. The Therapeutic Vaccines Market Report highlights these trends and opportunities, indicating a promising future for therapeutic vaccines as they expand their product pipeline and market share.


The therapeutic vaccines market size is projected to reach US$ 2,934.57 million by 2031 from US$ 1,244.94 million in 2024. The market is expected to register a CAGR of 13.0% during 2024–2031. Advancements in vaccine technology are likely to remain key trends in the therapeutic vaccines market.

Therapeutic Vaccines Market Analysis

The therapeutic vaccines market is expected to witness substantial growth in the coming years due to advancements in immunotherapy and the increasing prevalence of chronic diseases, such as cancer and infectious diseases. These vaccines are administered to treat diseases by stimulating the immune system to target and destroy diseased cells. The therapeutic vaccines market is poised for significant growth with a surging focus on personalized medicine and technological innovations. Factors such as government investments, rising healthcare demands, and novel vaccine platform development further contribute to its expansion. The market is expected to experience strong growth due to increasing healthcare investments, advancements in vaccine technologies, and a growing demand for targeted therapeutic solutions.

Therapeutic Vaccines Market Overview

The therapeutic vaccines market is rapidly evolving, fueled by advancements in immunotherapy and growing awareness of vaccine-based treatment approaches. The market is particularly driven by innovations in cancer immunotherapy, which involves developing therapeutics to enhance the immune system's ability to recognize and destroy tumor cells. The increasing prevalence of chronic diseases and the growing awareness of personalized medicine further stimulate the demand for therapeutic vaccines. The German Cancer Research Center (DKFZ) conducts pioneering research in cancer immunotherapy and vaccine development, contributing to the country's role as a hub for medical innovation. In August 2024, researchers at the DKFZ introduced a novel vaccine aimed at boosting HPV vaccination rates, targeting cancer-causing human papillomaviruses (HPV). This innovative vaccine is cost-effective and has shown efficacy in protecting mice from nearly all types of cancer-causing HPV. The vaccine also stimulates cellular immune responses against HPV-infected cells and has a therapeutic effect against existing infections. The ultimate objective of researchers is to develop a therapeutic vaccine for individuals who have already contracted HPV, particularly those who may have developed HPV-related cancer or precancerous lesions. Thus, a strong research ecosystem and collaborative efforts between academic institutions, hospitals, and biotech companies are accelerating the development of new therapeutic vaccines in Germany.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Therapeutic Vaccines Market: Strategic Insights

therapeutic-vaccines-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Therapeutic Vaccines Market Drivers and Opportunities

Rising Prevalence of Chronic Conditions Bolsters Market Growth

Chronic conditions such as cancer, neurological diseases, and autoimmune diseases are becoming more widespread globally due to factors such as aging, lifestyle changes, and environmental influence. According to the World Health Organization's (WHO) Noncommunicable Diseases Factsheet 2023, these diseases account for 41 million global deaths annually, equivalent to 74% of total mortality. Per the Global Cancer Facts & Figures, ~20 million cancer cases were diagnosed in 2022, and 9.7 million people succumbed to the disease in the same year. Moreover, as per an article titled "The Global Landscape of Autoimmune Disease," published in February 2024, autoimmune diseases affect 5–10% of the industrial world population; it also states that ~50 million Americans are affected by autoimmune diseases. In addition, as per the WHO multiple sclerosis factsheet, over 1.8 million people in the world suffered from multiple sclerosis as of August 2023.

Thus, the surging incidences of various chronic conditions highlight the urgent need for innovative therapeutic interventions. Therapeutic vaccines are designed to treat existing diseases instead of preventing their onset. These vaccines stimulate the body's immune system to target and treat specific diseases. In cancer treatment, the Sipuleucel-T (Provenge) vaccine has demonstrated the potential to improve survival rates in prostate cancer patients. Amid the demand for innovative treatments for chronic diseases, therapeutic vaccines are expected to offer a new approach to long-term disease management and improve patient outcomes globally. Thus, the rising prevalence of chronic diseases fuels the therapeutic vaccines market growth.

Extending Product Pipeline to Create Growth Opportunities

As the global demand for innovative treatment options rises, the therapeutic vaccines sector has witnessed robust investments and advancements in vaccine development, driven largely by the rising number of clinical candidates progressing through various stages of development. R&D efforts in biotechnology yield cutting-edge therapeutic vaccines that target various diseases, particularly newer infections and chronic ones such as cancer. Moderna's mRNA-4157 is currently in phase 2 trials, with early-stage results showing promising potential in combination with checkpoint inhibitors for melanoma treatment. In addition to oncology, the therapeutic vaccine pipeline is also growing in areas such as autoimmune diseases and infectious diseases (HIV, HPV, and HBV infections).

With the expanding pipeline of vaccine candidates targeting diverse diseases, therapeutic vaccines hold immense potential to address unmet medical needs. Thus, a strong pipeline of candidates for therapeutic vaccines signifies lucrative growth opportunities for the therapeutic vaccines market.

Therapeutic Vaccines Market Report Segmentation Analysis

Key segments that were the foundation of the therapeutic vaccines market analysis are product, technology, and end user.

  • Based on product, the therapeutic vaccines market is categorized into cancer vaccines, infectious disease vaccines, and others. The cancer vaccines segment held the largest share of the market in 2024.
  • Based on technology, the market is bifurcated into allogenic vaccines and autologous vaccines. The autologous vaccine segment held a larger therapeutic vaccines market share in 2024.
  • In terms of end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment dominated the market in 2024.

Therapeutic Vaccines Market Share Analysis by Geography

The geographic scope of the therapeutic vaccines market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America held a significant share of the market in 2024. The regional market growth is driven by rising cancer incidence, increasing investments in research and development, and a surge in product launches. Additionally, strategic initiatives such as the development of new products, regulatory approvals, collaborations, and acquisitions are further propelling the expansion of the therapeutic vaccine market in the region. According to the American Cancer Society, in 2022, more than 1.9 million new cases of cancer were diagnosed in the nation, causing ~0.61 million deaths. In 2024, 2.0 million people in the US were diagnosed with cancer. The rising number of cancer cases ultimately fuels the demand for innovative treatment options. Therapeutic vaccines, designed to stimulate the immune system to target cancer cells, offer promising alternatives to traditional therapies. In 2010, Provenge (sipuleucel-T) became the first therapeutic cancer vaccine to receive approval from the FDA. It is specifically designed for prostate cancer, highlighting the potential for immunotherapy to provide life-extending treatments. This rising number of cases propels research and development investments as well as encourages collaborations among companies and academic institutions.

The Canadian government plays a crucial role through funding initiatives and providing grants to support early-stage cancer research. In September 2024, researchers at the University of British Columbia (UBC) within Canada's Immuno-Engineering and Biomanufacturing Hub (CIEBH) were awarded over US$ 31.4 million in provincial funding for three projects aimed at advancing the development of vaccines and therapeutics in British Columbia for all Canadians. The funding, provided through the BC Knowledge Development Fund (BCKDF), will support the establishment of cutting-edge research infrastructure, including an Advanced Therapeutics Manufacturing Facility (ATMF) on UBC's Vancouver campus. This facility will enable the development and production of clinical-grade treatments that meet Health Canada's rigorous quality standards for clinical trials. These projects align with CIEBH's mission to position BC and Canada as global leaders in next-generation immune-based therapeutics, including mRNA vaccines, antibody treatments, and cell- and gene-based therapies.

Therapeutic Vaccines Market Regional Insights

The regional trends and factors influencing the Therapeutic Vaccines Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Therapeutic Vaccines Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

therapeutic-vaccines-market-global-geography
  • Get the Regional Specific Data for Therapeutic Vaccines Market

Therapeutic Vaccines Market Report Scope

Report Attribute Details
Market size in 2024 US$ 1,244.94 Million
Market Size by 2031 US$ 2,934.57 Million
Global CAGR (2024 - 2031) 13.0%
Historical Data 2021-2023
Forecast period 2024-2031
Segments Covered By Product
  • Cancer Vaccines
  • Infectious Disease Vaccines
By Technology
  • Allogenic Vaccines
  • Autologous Vaccines
By End User
  • Hospitals
  • Clinics
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd,
  • Merck & Co Inc,
  • Amgen Inc,
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc,
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

  • Therapeutic Vaccines Market Players Density: Understanding Its Impact on Business Dynamics

    The Therapeutic Vaccines Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

    Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

    Major Companies operating in the Therapeutic Vaccines Market are:

    1. Dendreon
    2. BioNTech SE
    3. Serum Institute of India Pvt. Ltd,
    4. Merck & Co Inc,
    5. Amgen Inc,
    6. ISA Pharmaceuticals BV

    Disclaimer: The companies listed above are not ranked in any particular order.


    therapeutic-vaccines-market-cagr

    • Get the Therapeutic Vaccines Market top key players overview

    Therapeutic Vaccines Market News and Recent Developments

    The therapeutic vaccines market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the therapeutic vaccines market are listed below:

    • TheraVectys has announced the enrollment of the first patient in Phase I/IIa clinical trial assessing the oncotherapeutic vaccine Lenti-HPV-07 for the treatment of HPV-induced cancers. Lenti-HPV-07 vaccine is based on the lentiviral vector technology platform developed by the Pasteur-TheraVectys Joint Laboratory, and TheraVectys has pioneered it over the past two decades. (Source: TheraVectys, Press Release, October 2024)
    • Serum Institute of India, the world's largest vaccine manufacturer by dose volume, entered into an exclusive global agreement with ImmunityBio, Inc., to supply Bacillus Calmette-Guerin (BCG) to ImmunityBio. The deal includes the production of standard BCG, approved for use outside the US, and a next-generation recombinant BCG (iBCG), currently undergoing testing. The iBCG is intended for use in combination with ImmunityBio's ANKTIVA for both approved and potential future indications, subject to regulatory approval. The two companies will collaborate to expedite the Phase 2 clinical trials of iBCG being conducted in Europe. (Source: Serum Institute of India Pvt. Ltd, Press Release, May 2024)

    Therapeutic Vaccines Market Report Coverage and Deliverables

    The "Therapeutic Vaccines Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

    • Therapeutic vaccines market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Therapeutic vaccines market trends and market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Therapeutic vaccines market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the therapeutic vaccines market
    • Detailed company profiles

    Frequently Asked Questions

    1
    What is the expected CAGR of the therapeutic vaccines market?
    The market is estimated to register a CAGR of 13.0% during the forecast period.
    2
    What are the factors driving the therapeutic vaccines market growth?
    The rising prevalence of chronic diseases, and increasing investments and funding for vaccine development are noteworthy factors contributing to the market growth.
    3
    What would be the estimated value of the therapeutic vaccines market by 2031?
    The market is estimated to reach a value of US$ 2,934.57 million by 2031.
    4
    Which are the leading players operating in the therapeutic vaccines market?
    Dendreon, BioNTech SE, Serum Institute of India Pvt. Ltd, Merck & Co Inc, Amgen Inc, ISA Pharmaceuticals BV, INOVIO Pharmaceuticals Inc, Transgene SA, THERAVECTYS SA, and CureVac SE are among the key players operating in the therapeutic vaccines market.
    5
    Which region dominated the therapeutic vaccines market in 2024?
    North America dominated the therapeutic vaccines market in 2024.
    Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Identifying Emerging Markets
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Boosting Operational Efficiency
    • Strategic Planning
    • Investment Justification
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Your Key Concerns Addressed - Question & Answer
    Can I view a sample of the report before purchasing?

    Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

    Is analyst support included with the purchase?

    Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

    What are the next steps once I place an order?

    Once your order is successfully placed, you will receive a confirmation email along with your invoice.

    • For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
    • For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

    Can the report be tailored to suit my specific needs?

    We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.

    In what format is the report delivered?

    The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

    The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
    Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

    How secure is the payment process on your platform?

    Our payment process is fully secure and PCI-DSS compliant.

    We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
    You can make your purchase with confidence, knowing your personal and financial information is safe with us.

    Do you provide special pricing for buying multiple reports?

    Yes, we do offer special pricing for bulk purchases.
    If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.

    Can I connect with your team to discuss the report before buying?

    Yes, absolutely.
    Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

    Will I get a billing invoice upon purchase?

    Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
    If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.

    Is there support available if I can’t access my report?

    Yes, certainly.
    If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.

    Our Clients

    The List of Companies - Therapeutic Vaccines Market

    • Dendreon
    • BioNTech SE        
    • Serum Institute of India Pvt. Ltd
    • Merck & Co Inc     
    • Amgen Inc.
    • ISA Pharmaceuticals BV    
    • INOVIO Pharmaceuticals Inc
    • Transgene SA       
    • THERAVECTYS SA          
    • CureVac SE
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo